Compare · LIVN vs PRKS
LIVN vs PRKS
Side-by-side comparison of LivaNova PLC (LIVN) and United Parks & Resorts Inc. (PRKS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LIVN and PRKS operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- LIVN is the larger of the two at $4.32B, about 2.9x PRKS ($1.48B).
- PRKS has been more active in the news (13 items in the past 4 weeks vs 2 for LIVN).
- LIVN has more recent analyst coverage (21 ratings vs 8 for PRKS).
- Company
- LivaNova PLC
- United Parks & Resorts Inc.
- Price
- -
- -
- Market cap
- $4.32B
- $1.48B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NYSE
- IPO
- 2013
- News (4w)
- 2
- 13
- Recent ratings
- 21
- 8
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Latest LIVN
- Barclays initiated coverage on LivaNova with a new price target
- LivaNova to Announce Third-Quarter 2026 Results
- SEC Form 4 filed by Chief Legal Officer Liddy Anne M.
- Director Bianchi Francesco sold $273,032 worth of Ordinary Shares (3,500 units at $78.01), decreasing direct ownership by 44% to 4,434 units (SEC Form 4)
- Director Story Brooke sold $187,270 worth of Ordinary Shares (2,300 units at $81.42), decreasing direct ownership by 23% to 7,488 units (SEC Form 4)
- LivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in September
- Director Bianchi Francesco sold $131,538 worth of Ordinary Shares (1,650 units at $79.72), decreasing direct ownership by 17% to 7,934 units (SEC Form 4)
- SEC Form 3 filed by new insider Liddy Anne M.
- Chief Innovation Officer Tezel Ahmet exercised 12,692 units of Ordinary Shares at a strike of $52.68, returned $668,740 worth of Ordinary Shares to the company (8,589 units at $77.86), covered exercise/tax liability with 1,428 units of Ordinary Shares and sold $207,942 worth of Ordinary Shares (2,675 units at $77.74) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by LivaNova PLC
Latest PRKS
- UNITED PARKS & RESORTS INC. ANNOUNCES THIRD QUARTER 2026 EARNINGS RELEASE DATE AND CONFERENCE CALL INFORMATION
- Director Hartnett Timothy was granted 2,641 shares, increasing direct ownership by 3% to 84,019 units (SEC Form 4)
- Director Schaefer Kimberly was granted 602 shares, increasing direct ownership by 1% to 43,342 units (SEC Form 4)
- Director Narang Neha Jogani was granted 1,204 shares, increasing direct ownership by 2% to 58,580 units (SEC Form 4)
- Director Lipman Nathaniel was granted 301 shares, increasing direct ownership by 1% to 20,617 units (SEC Form 4)
- Director Gray William was granted 1,825 shares, increasing direct ownership by 2% to 78,546 units (SEC Form 4)
- Large owner Hill Path Capital Partners Co-Investment S Lp was granted 2,641 shares (SEC Form 4)
- Large owner Hill Path Capital Partners Lp was granted 2,641 shares (SEC Form 4)
- Director Chambers James P. was granted 1,592 shares, increasing direct ownership by 2% to 67,150 units (SEC Form 4)
- Chief Executive Officer Swanson Marc was granted 59,524 shares, increasing direct ownership by 15% to 447,454 units (SEC Form 4)